Category: MedtronicSyndicate content

Medtronic begins U.S. IDE trial for Evera SureScan MRI-safe ICD

April 23, 2014 by Brad Perriello

Medtronic announces the 1st implantation in a U.S. investigational device exemption trial for its Evera SureScan MRI-safe implantable cardioverter-defibrillator.

Medtronic begins U.S. IDE trial for Evera SureScan MRI-safe ICD

Medtronic (NYSE:MDT) said the 1st patient was implanted with its MRI-safe Evera SureScan ICD as part of an investigational device exemption trial in the U.S.

Bakris: Symplicity-3 a prologue for renal denervation | MassDevice.com On Call

April 22, 2014 by MassDevice

Dr. George Bakris, co-principal investigator in Medtronic's Symplicity-3 trial, says renal denervation needs more study before attempting more clinical trials.

MassDevice.com On Call

MASSDEVICE ON CALL — Dr. George Bakris, the co-principal investigator for Medtronic's (NYSE:MDT) failed Symplicty-3 renal denervation trial, believes further clinical work should be tabled until a few key questions about the therapy are answered.

Appeals court stays ban on Medtronic's CoreValve device

April 21, 2014 by Brad Perriello

A federal appeals court stays a ban on U.S. sales of Medtronic's CoreValve replacement heart valve "pending further notice" in a patent infringement battle with Edwards Lifesciences and its Sapien transcatheter aortic valve implant.

Appeals court stays ban on Medtronic's CoreValve device

Edwards Lifesciences decries Medtronic's 'scare tactics' in CoreValve dispute

April 21, 2014 by Brad Perriello

Edwards Lifesciences urges a federal appeals court to ignore Medtronic's alleged 'scare tactics' over a pending ban on its CoreValve replacement heart valve.

Edwards Lifesciences decries Medtronic's 'scare tactics' in CoreValve dispute

UPDATED April 21, 2014, at 12:30 p.m. with comment from Medtronic.

UPDATED April 21, 2014, at 3:45 p.m. with comment from Edwards Lifesciences.

Medtronic touts Endurant stent graft data

April 18, 2014 by Brad Perriello

Medtronic touts positive data from a pair of clinical trials for its Endurant stent graft for treating abdominal aortic aneurysms.

Medtronic touts Endurant stent graft data

Medtronic (NYSE:MDT) said data from a pair of clinical trials evaluating its Endurant stent graft for abdominal aortic aneurysms "affirm the Endurant stent graft's durable, consistent and proven outcomes."

TAVI: Judge chides Medtronic, Edwards offers consolation prize in infringement case

April 17, 2014 by Arezu Sarvestani

A U.S. District Judge defends a ban on Medtronic's newly approved CoreValve transcatheter aortic valve implantation system, saying the company willfully ignored the law in bringing the device to the U.S. after it was found to infringe on a patent held by Edwards Lifesciences.

Judge: Medtronic thumbed nose at the law in bringing CoreValve to U.S.

U.S. District Judge Gregory Sleet chided Medtronic (NYSE:MDT) this week after issuing a preliminary ban on the medtech titan's CoreValve transcatheter aortic valve implantation system.

Built on an AdaptiveTheme using Drupal by Michael Knapp  mknapp